Treatment of recurrent vulvovaginal candidiasis
Reading File
Finding Sources
Searching PubMed
"recurrent vulvovaginal candidiasis" AND treatment
Searching the Web
recurrent vulvovaginal candidiasis treatment guidelines 2024 2025
Reading File
Reading File
Reading Article
Reading File
Reading Article
Reading File
I now have all the information needed for a comprehensive answer.
Recurrent Vulvovaginal Candidiasis (RVVC): Treatment
Definition
RVVC is defined as ≥4 symptomatic episodes of VVC within one year (some sources use ≥3 unrelated to antibiotics). It affects ~5–9% of women. The diagnosis must be confirmed by microscopy AND fungal culture, as many women self-diagnose incorrectly — chronic atopic dermatitis and atrophic vulvovaginitis are common mimics. Burning (rather than itching) becomes the dominant symptom in RVVC. Non-albicans species (C. glabrata, C. tropicalis) account for 10–20% of RVVC cases and tend to be azole-resistant.
Step 1 — Induction (Achieve Mycologic Remission)
Before starting maintenance, a sustained-release induction regimen should eliminate active infection:
| Route | Regimen |
|---|---|
| Oral (preferred) | Fluconazole 150 mg every 72 h × 3 doses (days 1, 4, 7) |
| Topical (alternative) | Any topical azole for 7–14 days |
This achieves clinical and mycologic remission before maintenance begins. — Berek & Novak's Gynecology, p. 812–813; CDC STI Guidelines 2021
Step 2 — Maintenance Suppression (6 months)
First-line (Azole-sensitive C. albicans)
| Drug | Dose/Frequency | Duration |
|---|---|---|
| Oral fluconazole | 150 mg once weekly | 6 months |
| Oral itraconazole | 200 mg twice weekly | 6 months |
| Topical clotrimazole | 200 mg vaginally twice weekly | 6 months |
On weekly fluconazole, ~90% of women remain in remission during the maintenance period. After stopping, ~50% remain symptom-free at 12 months; the other half relapse and should restart suppressive therapy. — Berek & Novak's Gynecology, p. 813
A 2024 Bayesian network meta-analysis (17 RCTs, n=2,304) confirmed that weekly oral fluconazole/itraconazole, weekly oral oteseconazole, and weekly topical clotrimazole were equally effective in preventing early (24-week) recurrence. After therapy discontinuation (48–52 weeks), oteseconazole outperformed all others, reducing late recurrence by >90% [PMID: 39362128].
Step 3 — Newer / Alternative Agents
Oteseconazole (Vivjoa)
A novel oral azole with high selectivity for fungal CYP51 (minimal human CYP interactions). Approved specifically for RVVC in non-pregnant, non-childbearing-potential women. The 2024 network meta-analysis ranked it highest for sustained post-treatment prevention [PMID: 39362128].
Ibrexafungerp (Brexafemme)
A first-in-class triterpenoid glucan synthase inhibitor — the first non-azole oral agent for RVVC. The phase 3 CANDLE trial (2025, n=260) showed monthly oral ibrexafungerp (300 mg twice daily × 1 day, every 4 weeks × 6 doses) significantly reduced recurrence vs. placebo (70.8% vs 58.5% no mycological recurrence at test-of-cure; RR 1.22, 95% CI 1.03–1.43, P=0.019). Benefit persisted 4 months after the last dose. It is active against C. albicans and non-albicans species, including azole-resistant strains [PMID: 40752754].
Non-albicans Candida (Fluconazole-Resistant RVVC)
| Agent | Regimen |
|---|---|
| Boric acid (intravaginal) | 600 mg/day × 14 days — first-line for non-albicans species |
| Terconazole vaginal cream | Preferred topical when non-albicans is suspected (broader spectrum vs. C. tropicalis, C. glabrata) |
| Nystatin vaginal tablet | 100,000 U daily × 14 days — alternative |
| Flucytosine ± amphotericin B cream | For refractory C. glabrata |
Fluconazole failure should prompt fungal culture and species identification. — Berek & Novak's Gynecology, p. 813; Washington Manual, p. 626
Special Populations
| Situation | Approach |
|---|---|
| Pregnancy | Topical azoles only (7-day course); oral azoles contraindicated |
| Diabetes / HIV / Immunosuppression | Optimize glycemic control; may need prolonged topical regimens (10–14 days); specialist referral if refractory |
| Severe VVC | Fluconazole 150 mg × 2 doses (72 h apart) + 10–14 day topical ± low-potency topical steroid (1% hydrocortisone) for external symptoms |
| Postmenopausal | Rule out atrophic vaginitis; consider adjunctive vaginal estrogen |
Predisposing Factors to Address
- Antibiotic use — minimize unnecessary courses; consider prophylactic fluconazole when antibiotics unavoidable
- Uncontrolled diabetes — optimize glycemia
- Contraceptives — high-dose combined OCP may contribute; consider alternative
- HIV / immunosuppression — screen if recurrence is otherwise unexplained
Summary Algorithm
RVVC confirmed (≥4 episodes/year + culture)
↓
Culture species + susceptibility
↓
C. albicans Non-albicans / azole-resistant
↓ ↓
Induction: Fluconazole Boric acid 600 mg/day × 14 d
150 mg q72h × 3 doses ± Ibrexafungerp
↓
Maintenance × 6 months:
• Fluconazole 150 mg/week (oral)
• OR Oteseconazole (if no childbearing potential)
• OR Ibrexafungerp monthly
• OR Topical clotrimazole twice weekly
↓
Reassess at 6 months:
Remission → observe
Relapse → restart suppression
Key Recent Evidence:
- [PMID 39362128] — 2024 Bayesian network meta-analysis: oteseconazole superior post-discontinuation; fluconazole/itraconazole and clotrimazole equivalent during active treatment
- [PMID 40752754] — 2025 Phase 3 CANDLE trial: monthly ibrexafungerp significantly reduces RVVC recurrence (first non-azole oral maintenance option)
Sources: Berek & Novak's Gynecology, p. 811–813; Washington Manual of Medical Therapeutics, p. 626; CDC STI Treatment Guidelines 2021
This is a shared conversation. Sign in to Orris to start your own chat.